Phase 2 Study to Evaluate RPT193 in Adults With Moderate to Severe T2-high Asthma

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2023
Randomized, multi-center, double-blind, placebo-controlled, parallel group, proof of-concept study with RPT193 in subjects with T2-high, moderate-to-severe asthma who are partially controlled on medium or high doses of inhaled corticosteroids (ICS) in combination with long-acting beta 2 agonist (LABA).
Epistemonikos ID: 6b149ad159142ea5b971aac67e8e2942c73402c0
First added on: Oct 02, 2023